Next week, I’ll join thousands of biotechnology thinkers and leaders from around the world in San Francisco for the 2016 BIO International Convention. Edelman is a sponsor of BIO’s California Pavilion and will be convening a panel discussion with biotech leaders about the rise of trust inequality in the healthcare sector and its impact, both current and potential, on biotech leadership.

Trust is a critical asset to support the advancement and accessibility of new innovations in the sector, but according to the 2016 Edelman TRUST BAROMETER, consumer trust in the biotech industry has fallen in the U.S. Why does this matter? Trust is a fundamental aspect of a company’s license to operate and lead, as well as attract and keep employees in a highly competitive market. The Health & Trust infographic highlights many of the trust trends we found in this year’s data, comparing across sectors and within healthcare.

Moderated by biotech journalist Luke Timmerman, our esteemed panelists – senior executives from a number of biotech/life sciences companies – will discuss the implications of the erosion of trust in biotech in the U.S. and why this should be an early warning sign for biotech companies. We will talk about industry performance gaps and their potential causes, as well as what biotech and life science companies are and should be doing more of now to stem the tide and build trust in today’s populist environment.

If you’ll be at BIO, we’d love for you to join us.

Panel Details:
The Rise of Trust Inequality and its Impact on Biotech Leadership
Tuesday, June 7 from 1:00 – 1:30 pm PST
Moscone Center, California Pavilion
CLSA Main Stage; South Hall A-C

Susan Isenberg, vice chair, Health.